An Overview of EECP/ECP
EECP® (Enhanced External Counterpulsation) Therapy and ECP (External Counterpulsation) Therapy are the terms which describe the noninvasive, complimentary or alternative treatment prescribed by physicians for patients suffering from the symptoms of angina, congestive heart failure and other cardiovascular diseases. Both EECP Therapy, a name which has been trademarked by Vasomedical Inc., Plainview, NY in the marketing of their treatment method and treatment devices they manufacturer and ECP Therapy, the generic term used to describe all other forms of external counterpulsation (including the ECP systems manufactured by PSK – Chongqing, China) , are based upon the proven hemodynamic principal of counterpulsation, which involves increasing blood flow (volume and pressure) to the heart during diastole (when the heart is at rest) and reducing the workload and oxygen demand the heart uses to pump blood throughout the body in systole.
In addition to the clinically proven hemodynamic principal of counterpulsation, extensive research in clinical studies published in peer-reviewed medical journals have demonstrated the many mechanisms of action that are responsible for the initial benefits produced by the therapy as well as the long term outcomes, which show these initial benefits lasting three to five years. While every year a number of clinical articles on EECP and ECP continue to be published in medical journals and textbooks worldwide, some using PSK ECP systems and supported by PSK, most of the over 200 clinical articles published in the literature on EECP and ECP therapy were performed on Vasomedical EECP therapy systems and reported in the clinical research supported by Vasomedical.
Contact our professional VSK sales & marketing team today to discuss the clinical and financial benefits of EECP/ECP therapy, and which of the various therapy systems available through VSK will best meet your needs.